Global Paroxysmal Nocturnal Hemoglobinuria Drug Market - Industry Trends and Forecast to 2029

Market Analysis and Insights Global Paroxysmal Nocturnal Hemoglobinuria Drug Market

Paroxysmal nocturnal hemoglobinuria drug market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 12.31% in the above mentioned forecast period. Increase in the special designation from the regulatory authority and presence of refined healthcare infrastructure are the factors for enhancing the market growth.

Paroxysmal nocturnal hemoglobinuria is a rare blood disorder that causes the premature breakdown of red blood cells (hemolysis). This condition occurs when the body's immune system attacks and destroys red blood cells due to a lack of a protein that protects them. Dark or bright red blood in the urine, anaemia, blood clotting in the veins, headaches, tiredness, shortness of breath, and pale yellow skin are all symptoms of this disorder.

The global paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market is expected to grow significantly over the forecast period, owing to increasing number of paroxysmal nocturnal hemoglobinuria (PNH) treatment approvals from the U.S. Food and Drug Administration (FDA), which include iron supplements, blood transfusion, blood thinner, eculizumab (soliris), and bone marrow transplant. Furthermore, new research and development studies are being conducted to develop cost-effective paroxysmal nocturnal hemoglobinuria (PNH) treatment, which is expected to drive the revenue of the paroxysmal nocturnal hemoglobinuria therapeutics market.

The rising prevalence of blood disorders is propelling the market forward. The emergence of biologics that target the cause of a hemolytic defect or an abnormal hematopoietic stem cell is expected to drive market growth during the forecast period. High unmet drug demand in developing countries is also propelling market growth. Increased investment from government, public, and private organisations in the development of novel drugs is driving market growth.

However, the high cost of therapy and surgical procedures, such as stem cell transplants (SCT), is limiting market growth. Adverse side effects of available treatments may impede market growth during the forecast period. The market's growth is being hampered by an unfavourable reimbursement environment in developing regions. The risks associated with bone marrow transplantation are impeding market growth

This paroxysmal nocturnal hemoglobinuria drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the paroxysmal nocturnal hemoglobinuria drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Scope and Market Size

Paroxysmal nocturnal hemoglobinuria drug market is segmented of the basis of treatment, drugs, route of administration, distribution channel and end user. The growth among these specific segments will help users analyze niche pockets of growth and strategies to approach the market and determine your core application areas and difference in your target markets.

• Based on treatment, the paroxysmal nocturnal hemoglobinuria drug market is segmented as medication, supplements, blood transfusion, and bone marrow transplant
• Based on drugs, the paroxysmal nocturnal hemoglobinuria drug market is segmented as eculizumab, ravulizumab and others
• Based on the route of administration, the paroxysmal nocturnal hemoglobinuria drug market is segmented into oral and parenteral
• Based on the distribution channel, the paroxysmal nocturnal hemoglobinuria drug market is segmented as direct, online pharmacy, retailers and others
• Based on end user, the paroxysmal nocturnal hemoglobinuria drug market is segmented into hospitals, homecare, specialty clinics and others

Paroxysmal Nocturnal Hemoglobinuria Drug Market Country Level Analysis

Paroxysmal nocturnal hemoglobinuria drug market is analyzed and market size information is provided by the country, treatment, drugs, route of administration, distribution channel and end user as referenced above.

The countries covered in the paroxysmal nocturnal hemoglobinuria drug market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the paroxysmal nocturnal hemoglobinuria drug market due to the presence of major key players, increasing the penetration of episodic treatments and the increase of immunoglobulin reimbursement in the U. S., as well as the growth of the aging population. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector as well as rising low cost treatment and medical tourism for treatment of paroxysmal nocturnal hemoglobinuria.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Paroxysmal nocturnal hemoglobinuria drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to paroxysmal nocturnal hemoglobinuria (PNH) market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the paroxysmal nocturnal hemoglobinuria (PNH) market in the growth period.

Competitive Landscape and Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share Analysis

The paroxysmal nocturnal hemoglobinuria drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to paroxysmal nocturnal hemoglobinuria drug market research.

Some of the major players operating in the paroxysmal nocturnal hemoglobinuria drug market are Alexion Pharmaceuticals, Inc, Akari Therapeutics, Plc, Apellis Pharmaceuticals, CinnaGen Co, Ra Pharmaceuticals, Inc, Amgen Inc, Alnylam Pharmaceuticals, Inc, Achillion Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Regeneron Pharmaceuticals, Inc, BIOCAD, Samsung Bioepis, Amyndas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, NorthStar Rx LLC, Abbott, Cook and Par Pharmaceutical among others.

SKU-50503